Compare MLSS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | VTGN |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 25.3M |
| IPO Year | 1996 | 2014 |
| Metric | MLSS | VTGN |
|---|---|---|
| Price | $0.41 | $0.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $1.00 | $0.90 |
| AVG Volume (30 Days) | 170.2K | ★ 4.1M |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | $124.49 |
| Revenue Next Year | $8.99 | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $0.20 |
| 52 Week High | $0.68 | $5.14 |
| Indicator | MLSS | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 31.15 |
| Support Level | $0.24 | $0.20 |
| Resistance Level | $0.44 | $0.66 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 66.86 | 39.06 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.